APVO Aptevo: Enterprise Value to Sales Volume

Official company branding of Aptevo (APVO)

The EV/Sales ratio on the GURU.Markets base chart demonstrates the valuation of Aptevo Therapeutics (APVO), whose ADAPT oncology ecosystem links pharma giants through long-term licenses. The development of ADAPTIR precision antibodies aims for the targeted destruction of tumors via T-cells. Meanwhile, 0.00 represents the current value of this metric, considering the FDA's influence on drug toxicity in AML treatment and the influx of R&D capital.

APVO (Aptevo) EV/Sales Multiple history from 11/23/2025 to 11/20/2026

APVO (Aptevo): analytical breakdowns and indicator data

- current quotes and average value forecast:
Fundamental valuation:Aptevo Therapeutics APVO
Flagship merchandise of Aptevo Therapeutics, Inc.

This metric measures the total enterprise value, including net debt, relative to a unit of revenue, allowing for an assessment of the asset's real value regardless of financial leverage. By analyzing the EV/Sales ratio, an investor can determine how the market currently prices in the potential of the Aptevo Therapeutics (APVO) bispecific antibody platform, accounting for the risks of its narrow clinical portfolio and the support of strategic partners.

Direct competitors

ARGX - EV/Sales Multiple|BNTX: EV/Sales Multiple|ABVX (Abivax SA) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio ADMA Corp|Enterprise Value-to-Revenue Multiple Protagonist Therapeutics PTGX|Company Value to Revenue IMVT (Immunovant Therapeutics)|Total Company Value-to-Revenue Ratio kiniksa.com|Enterprise Value-to-Revenue Ratio Grifols Biemat GRFS|Enterprise Value-to-Revenue Coefficient ADPT (Adaptive Biotechnologies Corporation)|celldex.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Aurinia Pharma AUPH|biocryst.com (BCRX) - Enterprise Value-to-Revenue Ratio|Vera Therapeutics, Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Dianthus Therapeutics Inc|Pharvaris NV (PHVS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple ABCL|Tourmaline Corp - Company Value to Revenue Ratio|EV/Sales Multiple PGEN (precigen.com)|Enterprise Value-to-Sales Ratio pharming.com|NKTR - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Upstream Bio Corp|ZBIO: EV/Sales Multiple|Company Value to Revenue Immunome, Inc.|Company Value to Revenue GOSS|KALV: Business Value to Revenue|EV/Sales Multiple SEPN|Company Value to Revenue Pieris Pharmaceuticals, Inc. PVLA|EV/Sales Multiple SVRA (Savara Inc)|EV/Sales Multiple Rigel Pharmaceuticals RIGL|AnaptysBio Inc. - EV/Sales Multiple|Astria Therapeutics - Enterprise Value-to-Revenue Coefficient|ENGN: EV/Sales Multiple|RAPT - Total Company Value-to-Revenue Ratio|Company Value to Revenue JBIO|Aclaris (ACRS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple KYTX|Company Value to Revenue Tiziana Life Sciences TLSA|EV/Sales Multiple CABA (cabalettabio.com)|Enterprise Value-to-Revenue Coefficient VTYX (Ventyx Bio)|Theratechnologies, Inc - EV/Sales Multiple|AVTX (Avalo Therapeutics Inc.) - Company Value to Revenue Ratio|eledon.com (ELDN) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio AGEN|CLYM (climbbio.com) - EV/Sales Multiple|EV/Sales Multiple zurabio.com|Enterprise Value-to-Revenue Ratio aTyr (ATYR)|ADAG - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio ImageneBio Inc IMA|EV/Sales Multiple Shattuck Labs, Inc. STTK|EQ - Enterprise Value-to-Revenue Ratio|connectbiopharm.com (CNTB) - Company Value to Revenue|IMUX (Immunic) - Company Value to Revenue|Atara Biotherapeutics, Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio InflaRx|Company Value to Revenue x4pharma.com (XFOR)|EV/Sales Multiple ACET|Company Value to Revenue Celularity Corp CELU|INmune Bio Inc - Company Value to Revenue|BRNS (Barinthus Bio) - Enterprise Value to Sales Volume|KZR - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio sabbiotherapeutics.com SABS|Akari Therapeutics PLC (AKTX) - Enterprise Value-to-Revenue Ratio|ENLV - Total Company Value-to-Revenue Ratio|QTTB (Q32 Bio) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple GeoVax Labs Inc GOVX|Enterprise Value-to-Revenue Ratio Edesa Biotech (EDSA)|Company Value to Revenue iBio IBIO|Carisma Therapeutics Inc - Company Value to Revenue|XTLB - Company Value to Revenue|BOLT - Enterprise Value-to-Revenue Ratio|Business Value to Revenue HCWB (hcwbiologics.com)|AIM (AIM ImmunoTech, Inc.) - Company Value to Revenue|Aditxt Corp - Business Value to Revenue|GRI (GRI Bio Inc) - EV/Sales Multiple|EV/Sales Multiple XORTX Therapeutics Inc|Enterprise Value-to-Revenue Ratio Vyome Therapeutics (HIND)|REVB - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio Indaptus Therapeutics, Inc. INDP|EV/Sales Multiple scinai.com SCNI|CalciMedica Inc - EV/Sales Multiple|AFMD - EV/Sales Multiple|ALLK: EV/Sales Multiple|Enterprise Value to Sales Volume HOOK (HOOKIPA Pharma, Inc.)|IGMS (IGM Biosciences) - EV/Sales Multiple|ITOS: Business Value to Revenue|Company Value to Revenue OCEA (Ocean Biomedical)|TCBP: Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio Third Harmonic Bio Inc THRD